|
1
|
Trousseau A: Phlegmasia alba dolens.
Lectures on Clinical Medicine, delivered at the Hotel-Dieu, Paris.
5:(London, England). New Sydenham Society. 281–332. 1865.
|
|
2
|
Sack GH Jr, Levin J and Bell WR:
Trousseau's syndrome and other manifestations of chronic
disseminated coagulopathy in patients with neoplasms: Clinical,
pathophysiologic, and therapeutic features. Medicine (Baltiinore).
56:1–37. 1977. View Article : Google Scholar
|
|
3
|
Viselli AL, Feuer GA and Granai CO: Lower
limb ischemic venous thrombosis in patients with advanced ovarian
carcinoma. Gynecol Oncol. 49:262–265. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Planner RS, O'Sullivan EF, Campbell JJ and
Ball DL: The hypercoagulable state and pulmonary embolism in
patients with ovarian carcinoma. Aust N Z J Obstet Gynaecol.
18:209–212. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ito S, Yoshitomi H, Pak M, Kawahara H,
Oshima T, Ito S, Watanabe N, Sato H, Adachi T, Takeda M, et al:
Trousseau syndrome with nonbacterial thrombotic endocarditis in a
patient with uterine cancer. Intern Med. 52:1353–1358. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shao B, Wahrenbrock MG, Yao L, David T,
Coughlin SR, Xia L, Varki A and McEver RP: Carcinoma mucins trigger
reciprocal activation of platelets and neutrophils in a murine
model of Trousseau syndrome. Blood. 118:4015–4023. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Levitan N, Dowlati A, Remick SC, Tahsildar
HI, Sivinski LD, Beyth R and Rimm AA: Rates of initial and
recurrent thromboembolic disease among patients with malignancy
versus those without malignancy. Risk analysis using Medicare
claims date. Medicine (Baltimore). 78:285–291. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vernon S: Trousseau's syndrome:
Thrombophlebitis with carcinoma. J Abdom Surg. 3:137–138.
1961.PubMed/NCBI
|
|
9
|
Cestari DM, Weine DM, Panageas KS, Segal
AZ and DeAngelis LM: Stroke in patients with cancer: Incidents and
etiology. Neurology. 62:2025–2030. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang YY, Chan DK, Cordato D, Shen Q and
Sheng AZ: Stroke risk factor, pattern and outcome in patients with
cancer. Acta Neurol Scand. 114:378–383. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bell WR, Starksen NF, Tong S and
Porterfield JK: Trousseau's syndrome. Devastating coagulopathy in
the absence of heparin. Am J Med. 79:423–430. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Krauth D, Holden A, Knapic N, Liepman M
and Ansell J: Safety and efficacy of long-term oral anticoagulation
in cancer patients. Cancer. 59:983–985. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Walsh-McMonagle D and Green D:
Low-molecular-weight heparin in the management of Trousseau's
syndrome. Cancer. 80:649–655. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Meyer G, Marjanovic Z, Valcke J, Lorcerie
B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P and
Farge D: Comparison of low-molecular-weight heparin and warfarin
for the secondary prevention of venous thromboembolism in patients
with cancer: A randomized controlled study. Arch Intern Med.
162:1729–1735. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Levine MN: Managing thromboembolic disease
in the cancer patient: Efficacy and safety of antithrombotic
treatment options in patients with cancer. Cancer Treat Rev.
28:145–149. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Castelli R, Porro F and Tarsia P: The
heparins and cancer: Review of clinical trials and biological
properties. Vasc Med. 9:205–213. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zacharski LR and Loynes JT:
Low-molecular-weight heparin in oncology. Anticancer Res.
23:2789–2793. 2003.PubMed/NCBI
|
|
18
|
McCart GM and Kayser SR: Therapeutic
equivalency of low-molecular-weight heparins. Ann Pharmacother.
36:1042–1057. 2002. View Article : Google Scholar : PubMed/NCBI
|
